STERIS (NYSE:STE) Releases Earnings Results, Beats Expectations By $0.03 EPS

STERIS (NYSE:STE) announced its quarterly earnings results on Wednesday. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.11 by $0.03, Briefing.com reports. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The company had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the prior year, the company posted $2.03 EPS. STERIS’s revenue was up 7.3% compared to the same quarter last year. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Stock Down 5.9 %

STERIS stock traded down $13.42 on Thursday, hitting $214.10. 708,413 shares of the stock traded hands, compared to its average volume of 485,029. The business’s fifty day simple moving average is $233.17 and its 200 day simple moving average is $227.60. The firm has a market cap of $21.11 billion, a P/E ratio of 52.93 and a beta of 0.85. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. STERIS has a 1 year low of $195.47 and a 1 year high of $248.24.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be issued a $0.57 dividend. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a yield of 1.06%. STERIS’s dividend payout ratio (DPR) is 56.58%.

Insider Buying and Selling

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.14% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have issued reports on STE. KeyCorp increased their target price on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. JMP Securities reiterated a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Wednesday, August 7th. Stephens reiterated an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research note on Thursday. Finally, Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $253.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.